
WilmerHale Reps Ocular Therapeutix™ in Strategic Collaboration With Regeneron

OCTOBER 13, 2016

Ocular Therapeutix, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has entered into a strategic collaboration, option and license agreement with Regeneron Pharmaceuticals, Inc. Ocular and Regeneron will collaborate on the development of a sustained release formulation of the vascular endothelial growth factor (VEGF) trap aflibercept for the treatment of wet age-related macular degeneration (wet AMD) and other serious retinal diseases.

WilmerHale represented Ocular in this transaction.

To read Ocular's press release visit www.ocutx.com.